AKBA
Price
$1.37
Change
-$0.04 (-2.84%)
Updated
Feb 4 closing price
Capitalization
360.9M
35 days until earnings call
Intraday BUY SELL Signals
TLPH
Price
$0.80
Change
-$0.07 (-8.05%)
Updated
Feb 4 closing price
Capitalization
37.62M
Intraday BUY SELL Signals
Interact to see
Advertisement

AKBA vs TLPH

Header iconAKBA vs TLPH Comparison
Open Charts AKBA vs TLPHBanner chart's image
Akebia Therapeutics
Price$1.37
Change-$0.04 (-2.84%)
Volume$3M
Capitalization360.9M
Talphera
Price$0.80
Change-$0.07 (-8.05%)
Volume$334.01K
Capitalization37.62M
AKBA vs TLPH Comparison Chart in %
AKBA
Daily Signal:
Gain/Loss:
TLPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AKBA vs. TLPH commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and TLPH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (AKBA: $1.37 vs. TLPH: $0.80)
Brand notoriety: AKBA and TLPH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKBA: 99% vs. TLPH: 90%
Market capitalization -- AKBA: $360.9M vs. TLPH: $37.62M
AKBA [@Pharmaceuticals: Generic] is valued at $360.9M. TLPH’s [@Pharmaceuticals: Generic] market capitalization is $37.62M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileTLPH’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • TLPH’s FA Score: 0 green, 5 red.
According to our system of comparison, TLPH is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 6 TA indicator(s) are bullish while TLPH’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 6 bullish, 2 bearish.
  • TLPH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than TLPH.

Price Growth

AKBA (@Pharmaceuticals: Generic) experienced а -5.52% price change this week, while TLPH (@Pharmaceuticals: Generic) price change was -19.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.90%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was +12.73%.

Reported Earning Dates

AKBA is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($361M) has a higher market cap than TLPH($37.6M). AKBA YTD gains are higher at: -14.907 vs. TLPH (-30.096). AKBA has higher annual earnings (EBITDA): 21.2M vs. TLPH (-12.46M). AKBA has more cash in the bank: 166M vs. TLPH (21.3M). TLPH has less debt than AKBA: TLPH (3.37M) vs AKBA (52.6M). AKBA has higher revenues than TLPH: AKBA (225M) vs TLPH (28K).
AKBATLPHAKBA / TLPH
Capitalization361M37.6M960%
EBITDA21.2M-12.46M-170%
Gain YTD-14.907-30.09650%
P/E RatioN/AN/A-
Revenue225M28K803,571%
Total Cash166M21.3M779%
Total Debt52.6M3.37M1,561%
FUNDAMENTALS RATINGS
AKBA vs TLPH: Fundamental Ratings
AKBA
TLPH
OUTLOOK RATING
1..100
353
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8849
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLPH's Valuation (57) in the Pharmaceuticals Other industry is in the same range as AKBA (59) in the Biotechnology industry. This means that TLPH’s stock grew similarly to AKBA’s over the last 12 months.

TLPH's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as AKBA (100) in the Biotechnology industry. This means that TLPH’s stock grew similarly to AKBA’s over the last 12 months.

TLPH's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as AKBA (100) in the Biotechnology industry. This means that TLPH’s stock grew similarly to AKBA’s over the last 12 months.

TLPH's Price Growth Rating (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for AKBA (88) in the Biotechnology industry. This means that TLPH’s stock grew somewhat faster than AKBA’s over the last 12 months.

TLPH's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as AKBA (100) in the Biotechnology industry. This means that TLPH’s stock grew similarly to AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBATLPH
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signal:
Gain/Loss:
TLPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TINFF0.310.01
+4.72%
Tincorp Metals Inc.
SHMDF114.09N/A
N/A
Shimano Inc.
SHALY11.44N/A
N/A
Shangri-La Asia Ltd.
ASMLF1337.90-53.45
-3.84%
ASML Holding N.V.
AXREF0.91-0.04
-3.87%
Amarc Resources Ltd.

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with SXTC. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then SXTC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-2.84%
SXTC - AKBA
62%
Loosely correlated
-13.02%
PRGO - AKBA
61%
Loosely correlated
+4.03%
TKNO - AKBA
53%
Loosely correlated
-5.74%
ALVO - AKBA
49%
Loosely correlated
-2.30%
SHPH - AKBA
45%
Loosely correlated
-12.50%
More

TLPH and

Correlation & Price change

A.I.dvisor tells us that TLPH and ALVO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPH and ALVO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPH
1D Price
Change %
TLPH100%
-8.81%
ALVO - TLPH
31%
Poorly correlated
-2.30%
AKBA - TLPH
30%
Poorly correlated
-2.84%
HIMS - TLPH
30%
Poorly correlated
-4.46%
PRGO - TLPH
25%
Poorly correlated
+4.03%
ZOMDF - TLPH
25%
Poorly correlated
+2.29%
More